Design and release kinetics of liposomes containing abiraterone acetate for treatment of prostate cancer
نویسندگان
چکیده
منابع مشابه
Abiraterone acetate: redefining hormone treatment for advanced prostate cancer.
Prostate cancer has long since been recognised as being hormonally driven via androgen receptor signalling. Abiraterone acetate (AA) is a rationally designed CYP17 inhibitor that blocks the conversion of androgens from non-gonadal precursors effectively, thus reducing testosterone to undetectable levels. AA has recently been proved to extend survival for men with metastatic castration-resistant...
متن کاملcomparison of zoe and vitapex for canal treatment of necrotic primary teeth
چکیده ندارد.
15 صفحه اولAbiraterone acetate for metastatic castration-resistant prostate cancer post-docetaxel
Abiraterone acetate (AA) 1000-mg daily, a selective irreversible androgen biosynthesis inhibitor of cytochrome P450 c17 (CYP17) enzyme, is used in combination with prednisone 10-mg daily to treat docetaxel-treated patients with metastatic castration-resistant prostate cancer (mCRPC). Several studies have demonstrated the safety and efficacy of this compound in men with mCRPC. Interim results fr...
متن کاملAbiraterone acetate: oral androgen biosynthesis inhibitor for treatment of castration-resistant prostate cancer
Prostate cancer is the second leading cause of cancer death in men in the US and Europe. The treatment of advanced-stage prostate cancer has been androgen deprivation. Medical castration leads to decreased production of testosterone and dihydrotestosterone by the testes, but adrenal glands and even prostate cancer tissue continue to produce androgens, which eventually leads to continued prostat...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Sensors International
سال: 2021
ISSN: 2666-3511
DOI: 10.1016/j.sintl.2020.100077